Pierre Geborek
81 – 100 of 135
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2008
-
Mark
Hand function tests are important and sensitive tools for assessment of treatment response in patients with rheumatoid arthritis.
(
- Contribution to journal › Article
-
Mark
Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
(
- Contribution to journal › Article
-
Mark
Health utilities improvement during TNF blockade in chronic arthritis occurs early in the treatment course, results from an eight year observational study in southern Sweden
2008) 72nd Annual Scientific Meeting of the American-College-of-Rheumatology/43rd Annual Scientific Meeting of the Association-of-Rheumatology-Health-Professionals In Arthritis and Rheumatism 58(9). p.552-552(
- Contribution to journal › Published meeting abstract
-
Mark
Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden
(
- Contribution to journal › Article
- 2007
-
Mark
The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review.
(
- Contribution to journal › Article
-
Mark
Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
(
- Contribution to journal › Article
-
Mark
Treatment with TNF-blockers and mortality risk in patients with rheumatoid arthritis.
(
- Contribution to journal › Article
-
Mark
Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients.
(
- Contribution to journal › Article
-
Mark
Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof. Individuel monitorering af biotilgaengelighed og immunogenicitet-- sekundaerpublikation
(
- Contribution to journal › Article
-
Mark
Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease
(
- Contribution to journal › Article
- 2006
-
Mark
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab
(
- Contribution to journal › Article
-
Mark
The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden.
(
- Contribution to journal › Article
-
Mark
Allvarlig lungsjukdom vid RA och TNF-blockering--finns det ett samband?
(
- Contribution to journal › Article
-
Mark
Swedish registers to examine drug safety and clinical issues in RA
(
- Contribution to journal › Scientific review
-
Mark
Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.
(
- Contribution to journal › Article
-
Mark
Predictors of infusion reactions during infliximab treatment in patients with arthritis.
(
- Contribution to journal › Article
-
Mark
Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden
(
- Contribution to journal › Article
- 2005
-
Mark
Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden
(
- Contribution to journal › Article
-
Mark
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
(
- Contribution to journal › Article
-
Mark
Response criteria for rheumatoid arthritis in clinical practice - how useful are they?
(
- Contribution to journal › Article